Hemophilia Inhibitor Previously Untreated Patient Study (HIPS)
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Sponsor: Baxter Healthcare Corporation
Listed as NCT01652027, this observational or N/A phase trial focuses on Hemophilia A and remains completed. Sponsored by Baxter Healthcare Corporation, it has been updated 13 times since 2011, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
-
Dec 2020 — Jan 2021 [monthly]
Completed
Status: Active Not Recruiting → Completed
▶ Show 8 earlier versions
-
Nov 2020 — Dec 2020 [monthly]
Active Not Recruiting
-
Jul 2019 — Nov 2020 [monthly]
Active Not Recruiting
-
Jun 2018 — Jul 2019 [monthly]
Active Not Recruiting
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting
-
Apr 2018 — May 2018 [monthly]
Active Not Recruiting
Phase: NA → None
-
Nov 2017 — Apr 2018 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Aug 2017 — Nov 2017 [monthly]
Recruiting NA
-
Jan 2017 — Aug 2017 [monthly]
Recruiting NA
First recorded
Jul 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Baxter Healthcare Corporation
- Rho, Inc.
- The University of Texas Health Science Center, Houston
For direct contact, visit the study record on ClinicalTrials.gov .